Lupin Limited announced that its Abbreviated New Drug Application for brimonidine tartrate ophthalmic solution 0.025% has won FDA approval. An over-the-counter product, brimonidine tartrate ophthalmic solution 0.025% is indicated to relieve redness of the eye resulting from minor ocular irritations.

Lupin will market it as a generic equivalent to Bausch + Lomb’s Lumify (brimonidine tatrate 0.025%) eyedrops, which had annual sales of approximately $39 million in the United States according to IQVIA.